The University of Michigan Health System (UMHS) Web site does not provide specific medical advice and does not endorse any medical or professional service obtained through information provided on this site or any links to this site.
Use of the UMHS web site does not replace medical consultation with a qualified health or medical professional to meet the health and medical needs of you or others.
While the content of the UMHS web site is frequently updated, medical information changes rapidly and therefore, some information may be out of date, and/or contain inaccuracies or typographical errors.
New Taubman Prize trophy debuts
The new trophy for the Taubman Prize for Excellence in Translational Medical Research, which was designed in consultation with institute founder Mr. A. Alfred Taubman, was presented at the institute's Oct. 11 symposium. The modern sculpture was created using a novel 3D printing technique.
Call for applications
Taubman Institute to offer six new scholar grants
The institute is accepting applications through Dec. 1 for its flagshop Taubman Scholar grant program, which is open to clinician-scientists on the U-M Medical School Faculty. Grants are $150,000 per year for three years.
Click here for details
U-M offers new early detection prostate cancer test
Research by Taubman Scholar Dr. Arul Chinnaiyan has let to the development of a new test for prostate cancer that is far more accurate than the standard PSA test, the University of Michigan has announced.
Click here to read more.
news & events
Is there a link between tonsils and psoriasis?
Trial tested the effect of tonsillectomy on the skin disease
Taubman Emerging Scholar Dr. Johann Gudjonsson and colleagues found that people who had their tonsils removed showed improvment.
Click here to read the entire story
Fall Visiting Professor Lectures schedule
Distinguished guest speakers include experts in lung, muscle and nerve diseases
Click here for the lineup
Breast cancer clinical trial enrolling patients
Research by Taubman Scholar Dr. Max Wicha into breast cancer stem cells is the basis for a new human clinical trial of the drug Reparixin, which scientists hope will curb the growth of the tumor-fueling cells.